笑看风云
沈梦露加盟凯尔特人女足_我的网站
一 |
Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness.
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source.
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations.
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。
苏格兰凯尔特人女足俱乐部7月31日宣布，20岁的中国女足球员沈梦露正式加盟，转会完成仍需等待国际转会许可，合同期为2年，沈梦露也将和另一名中国女足球员沈梦雨成为队友。司职前锋的沈梦露去年8月加盟葡萄牙体育，成为首位效力葡超的中国女足球员。
二 | 由于机会较少，她今年1月转投另一支葡超球队欧伦竞技，之后获得不少出场机会。沈梦露7月30日已代表凯尔特人女足在格拉斯哥城女足杯比赛中登场，身披22号，她在社交平台上表示：“新的赛季希望可以交上一份满意的答卷！”凯尔特人官方回应称：“期待你在凯尔特人书写属于你的历史！”
。
Current article:http://h48plzi.bianneixuanbingqinyouxie.buzz/823eyr/20260826/836872.html
Published on:16:22:35
